There are currently four open clinical trials of STING agonists in cancer, including a small-molecule agonist, CRD3874-S1, for sarcoma and Merkel cell carcinoma (NCT06021626); IMSA101 in solid malignancies (NCT05846659; NCT05846646); and the immune cell–targeting drug conjugate, TAK-500 (NCT05070247). The gene discussed is STING1; the disease is cancer.